Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Sands Capital Life Sciences Pulse Fund II, L.P. reported a 6.80% stake in Acrivon Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2025 · Filed Aug 13, 2025
Sands Capital Life Sciences Pulse Fund II, L.P. reported a 6.80% stake in Acrivon Therapeutics, Inc., 2,122,605 shares, as a passive investor on Jun 30, 2025. Filed Aug 13, 2025 (Schedule 13G/A).
- Stake
- 6.80%
- Shares
- 2,122,605
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.80% | 2,122,605 |
| Sands Capital Alternatives, LLC | 6.80% | 2,122,605 |
| SANDS FRANK M. | 6.80% | 2,122,605 |
Source
Related
- Acrivon Therapeutics, Inc.
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Acrivon Therapeutics, Inc. shareholders
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Miller Mary · Oct 7, 2026
- Form 4 · Levin Michaela · Sep 2, 2026
- Form 4 · Blume-Jensen Peter · Aug 27, 2026
- Form 4 · Peterson Katharine · Aug 20, 2026
- Form 4 · Miller Mary · Aug 20, 2026